ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. AddLife AB's annualized return on capital (ROC %) for the quarter that ended in Mar. 2026 was 5.35%.
As of today (2026-06-29), AddLife AB's WACC % is 8.71%. AddLife AB's ROC % is 5.75% (calculated using TTM income statement data).
AddLife AB earns returns that do not match up to its cost of capital. It will destroy value as it grows.
AddLife AB (STU:1AD1) ROC % Explanation
ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. The reason book values of debt and equity are used is because the book values are the capital the company received when issuing the debt or receiving the equity investments.
There are four key components to this definition. The first is the use of operating income or EBIT rather than net income in the numerator. The second is the tax adjustment to this operating income or EBIT, computed as a hypothetical tax based on an effective or marginal tax rate. The third is the use of book values for invested capital, rather than market values. The final is the timing difference; the capital invested is from the end of the prior year whereas the operating income or EBIT is the current year's number.
Why is ROC % important?
Because it costs money to raise capital. A firm that generates higher returns on investment than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.
As of today, AddLife AB's WACC % is 8.71%. AddLife AB's ROC % is 5.75% (calculated using TTM income statement data).
AddLife AB earns returns that do not match up to its cost of capital. It will destroy value as it grows.
Be Aware
Like ROE % and ROA %, ROC % is calculated with only 12 months of data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
AddLife AB ROC % Related Terms
AddLife AB ROC % Historical Data
* Premium members only.
The historical data trend for AddLife AB's ROC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note:
The Operating Income data used here is four times the quarterly (Mar. 2026) data.
The tax rate is limited to between 0% and 100%.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
AddLife AB (STU:1AD1) has a ROC % of 5.35% as of Mar. 2026. Return on capital is the ratio of current-period net income to average two-period capital. View historical data on AddLife AB and its competitors.
Is AddLife AB's ROC % too high?
AddLife AB's current ROC % is 5.35%. The Medical Devices & Instruments industry median ROC % is 1.25. AddLife AB's value of 5.35% is 328% above this industry median. Overall, AddLife AB has a GF Score™ of 85/100, reflecting its overall financial health beyond just this single metric.
How does AddLife AB's ROC % compare to ISRG and BDX?
AddLife AB's ROC % of 5.35% can be compared against companies in the Medical Devices & Instruments industry. The industry median ROC % is 1.25. AddLife AB's value of 5.35% is 328% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC % for a Medical Devices & Instruments company?
The median ROC % among Medical Devices & Instruments companies is 1.25, based on 847 companies in the industry. Companies in the top quartile (top 25%) have a ROC % significantly above this median, while those in the bottom quartile fall well below. However, ROC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. AddLife AB's current ROC % of 5.35% is 328% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC % mean?
A high ROC % can signal that a stock is expensive relative to its fundamentals. Return on capital is the ratio of current-period net income to average two-period capital. View historical data on AddLife AB and its competitors. For the Medical Devices & Instruments industry, the median ROC % is 1.25 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. AddLife AB's current ROC % is 5.35%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AddLife AB stock overvalued right now?
AddLife AB (STU:1AD1) has a current ROC % of 5.35%. The stock's GF Value™ is €13.19, compared to a current price of €15.21 — trading 15.3% above its estimated fair value. The current ROC % is 5.35% and 328% above the Medical Devices & Instruments industry median of 1.25. AddLife AB's overall GF Score™ is 85/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC % calculated?
ROC % is calculated from a company's financial statements. For AddLife AB (STU:1AD1), the current ROC % is 5.35% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is AddLife AB (STU:1AD1) Overvalued in 2026?
Based on GuruFocus' analysis, AddLife AB stock appears to be overvalued.
The current stock price of €15.21 is trading 15.3% above its estimated GF Value™ of €13.19.
Key valuation signals for STU:1AD1:
ROC %: 5.35%
GF Value™: €13.19 vs. price of €15.21 (15.3% above fair value)
Industry Position: 328% above the Medical Devices & Instruments median
No single metric tells the full story. See the STU:1AD1 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
AddLife AB is engaged in the business of providing products, services, and advisory services. The company operates in two segments: Labtech and Medtech. The Labtech segment provides analytical instruments, equipment, microscopes, consumables, and reagents, as well as software support and technical service to laboratories in medicine, research, academia and the food and pharmaceutical industries. The Medtech segment includes a range that spans from basic consumables to instruments for surgical procedures, welfare technology, and assistive devices for the elderly and disabled. The majority of revenue is derived from the Medtech segment.
85GF Score
Get the complete analysis for STU:1AD1
ROC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:1AD1 has been successfully added to your 
